GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Gugal Dishakar
Country: Canada
Language: English (Spanish)
Genre: Business
Published (Last): 13 January 2005
Pages: 199
PDF File Size: 3.60 Mb
ePub File Size: 17.89 Mb
ISBN: 562-8-29140-836-6
Downloads: 37675
Price: Free* [*Free Regsitration Required]
Uploader: Nisida

Gemifloxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Gemifloxacin. Tolbutamide Vildagliptin may increase the hypoglycemic activities of Tolbutamide. Patients who experience dizziness novattis an adverse reaction should avoid driving vehicles or using machines. Each tablet contains Enalapril The risk or severity of angioedema can be increased when Enalapril is combined with Vildagliptin.

Beclomethasone dipropionate The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Beclomethasone dipropionate. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Gatifloxacin. Distribution The plasma protein binding of vildagliptin is low 9.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ziprasidone. A MACE occurred in 83 out of 9, 0. Galvus vildagliptin is a dipeptidyl peptidase 4 DPP-4 inhibitor intended for use as a once-daily oral treatment for patients with type 2 diabetes.

As dual oral therapy in combination with – metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin, – a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance, – a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.

  CD4052BE DATASHEET PDF

Vildagliptin – Wikipedia

Lixisenatide The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Lixisenatide. The incidence of hypoglycaemia in the overall population was 8.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Diazoxide. The incidence of peripheral oedema when vildagliptin mg daily noavrtis added to a maximum dose of background pioglitazone 45 mg once daily was 7.

Cinoxacin The therapeutic efficacy of Vildagliptin can be increased when used in combination with Cinoxacin. Hydroxyfasudil The therapeutic efficacy of Vildagliptin can be increased when used in combination with Hydroxyfasudil.

Vildagliptin – DrugBank

Sulfamoxole The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfamoxole. A clinical trial of vildagliptin in patients with New York Heart Association NYHA functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing congestive heart failure CHF versus placebo.

The therapeutic efficacy of Vildagliptin can be increased when used in combination with Ertugliflozin. Darunavir The therapeutic efficacy of Vildagliptin can be increased when used in combination with Darunavir.

Vildagliptin launched by Novartis for dual therapy in type 2 diabetes

Glyburide Vildagliptin may increase the hypoglycemic activities of Glyburide. Vorinostat The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Vorinostat. Betamethasone The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Betamethasone.

There is limited experience in patients with ESRD on haemodialysis. General disorders and administration site conditions. By raising GLP-1 levels the drug also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion. Sildenafil The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sildenafil. Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions.

  GAUBERT CLARINET FANTASY PDF

Shows how to apply the principles to achieve successful drug therapy. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Technetium Tcm ciprofloxacin. Darodipine The risk or severity of hypoglycemia can be increased when Darodipine is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Danazol.

Prenylamine The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Vildagliptin. Enalaprilat The risk or severity of angioedema can be increased when Vildagliptin is combined with Enalaprilat.

The therapeutic efficacy of Vildagliptin can be decreased when used in novatis with Beclomethasone dipropionate.

Galvus 50 mg Tablets

Indalpine The risk or severity of hypoglycemia can be increased when Indalpine is combined with Vildagliptin. Following a meal, gut incretin hormones are released.

The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sildenafil.

Flunarizine The risk or severity of hypoglycemia can be increased when Flunarizine is combined with Vildagliptin. Empagliflozin Empagliflozin may increase the hypoglycemic activities of Vildagliptin. The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Vildagliptin. Initial marketing-authorisation documents List item.